Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Mycophenolate Mofetil after Lung Transplantation
NCT00402532Phase 3Completed
- Sponsor
- Hannover Medical School
- Start
- Mar 2005
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in lung transplant rejection (2 arms), sponsored by Hannover Medical School. Primary endpoints: Incidence and severity of bronchiolitis obliterans syndrome at 2 years, Mortality at 2 years and 1 more. Started Mar 2005; status: completed.
02
Drugs
everolimus
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT00402532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402532.